Ocimum Acquires Isogen's Biomolecular Synthesis Division to Grow Oligo Play | GenomeWeb
NEW YORK (GenomeWeb News) — Ocimum Biosolutions has acquired the biomolecular synthesis segment of Dutch company Isogen Life Sciences, Ocimum said today.
 
Ocimum CEO Anuradha Acharya said the acquisition is “a significant step towards becoming a global oligo player,” and said the company will continue to look for strategic targets to expand its oligo-production capacity.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.